Serum IgA reactivity against GroEL of Streptococcus sanguinis and human heterogeneous nuclear ribonucleoprotein A2/B1 in patients with Behçet disease. (25th April 2013)

• Record Type: Journal Article
• Authors: Cho, S.B.; Zheng, Z.; Ahn, K.J.; Choi, M.J.; Cho, S.; Kim, D.‐Y.; Lee, H.S.; Bang, D.
• Is Part Of: British journal of dermatology. Volume 168:Number 5(2013:May)
• Page Start: 977
• Page End: 983
• Publication Date: 2013-04-25
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.12128
• Languages: English
• ISSNs: 0007-0963

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Summary</title> <p> <bold>Background </bold> Infectious agents, especially <italic>Streptococcus sanguinis</italic> and herpes simplex virus, have long been postulated as major triggering factors for Behçet disease (BD).</p> <p> <bold>Objectives </bold> To identify an anti‐<italic>S. sanguinis</italic> antigen reacting with serum IgA antibody in patients with BD.</p> <p> <bold>Methods </bold> We detected a target protein by proteomics analysis and evaluated serum IgA reactivity of 100 patients with BD against the identified streptococcal target protein and human heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1. Homologous epitope sequences between the streptococcal target protein and human hnRNP A2/B1 were also evaluated.</p> <p> <bold>Results </bold> Four protein bands were detected by immunoprecipitation, and chaperonin GroEL was identified by a proteomics analysis. Reactivity of serum IgA against recombinant <italic>S. sanguinis</italic> GroEL was detected in 77 of 100 patients with BD (77%) and in 21 of 70 healthy controls (30%). In addition, reactivity of serum IgA against human recombinant hnRNP A2/B1 was seen in 79 of 100 patients with BD (79%) and in eight of 70 healthy controls (11%). Among the eight distinctive epitopes with significant homology between <italic>S. sanguinis</italic> GroEL and human hnRNP A2/B1, the serum IgA reactivity of patients with BD was markedly higher with epitope 3 (hnRNP A2/B1 peptide 33–46 and GroEL peptide 57–70) and epitope 6 (hnRNP A2/B1 peptide 177–188 and GroEL peptide 347–358).</p> <p> <bold>Conclusion </bold> We identified an <italic>S. sanguinis</italic> GroEL protein as a target of serum anti‐<italic>S. sanguinis</italic> IgA antibody reactivity in patients with BD. In addition, patients with BD exhibited serum IgA reactivity against homologous epitope regions between <italic>S. sanguinis</italic> GroEL and human hnRNP A2/B1.</p> </abstract>